Doi Takashi, Shintaku Mika, Dingemann Jens, Ruttenstock Elke, Puri Prem
National Children's Research Centre, Our Lady's Children's Hospital, Dublin 12, Ireland.
Pediatr Surg Int. 2011 Feb;27(2):199-204. doi: 10.1007/s00383-010-2773-4.
Nitrofen-induced congenital diaphragmatic hernia (CDH) model has been widely used to investigate the pathogenesis of pulmonary hypoplasia (PH) in CDH. Recent studies have suggested that retinoids may be involved in the molecular mechanisms of PH in CDH. Prenatal treatment with retinoic acid (RA) has been reported to improve the growth of hypoplastic lung in the nitrofen CDH model. Midkine (MK), a RA-responsive growth factor, plays key roles in various organogenesis including lung development. In fetal lung, MK mRNA expression has its peak at E13.5-E16.5 and is markedly decreased during mid-to-late gestation, indicating its important role in early lung morphogenesis. We designed this study to investigate the hypothesis that the pulmonary MK gene expression is downregulated in the early lung morphogenesis in the nitrofen-induced PH, and to evaluate the effect of prenatal RA treatment on pulmonary MK gene expression in the nitrofen-induced CDH model.
Pregnant rats were exposed to either olive oil or nitrofen on day 9 of gestation (D9). Fetal lungs were harvested on D15, D18, and D21 and divided into control, nitrofen with or without CDH [CDH(+) or CDH(-)]. In addition, RA was given on days D18, D19, and D20 and fetal lungs were harvested on D21, and then divided into control + RA and nitrofen + RA. The pulmonary gene expression levels of MK were evaluated by real-time RT-PCR and statistically analyzed. Immunohistochemistry was also performed to examine protein expression/distribution of MK in fetal lung.
The relative mRNA expression levels of MK were significantly downregulated in nitrofen group compared to controls at D15 ((§)p < 0.01), whereas there were no significant differences at D18 and D21. MK gene expression levels were significantly upregulated in nitrofen + RA (0.71 ± 0.17) compared to the control (0.35 ± 0.16), CDH(-) (0.24 ± 0.15), CDH(+) (0.39 ± 0.19) and control + RA (0.47 ± 0.13) (*p < 0.05). Immunoreactivity of MK was also markedly decreased in nitrofen lungs compared to controls on D15, and increased in nitrofen + RA lungs compared to the other lungs on D21.
Downregulation of MK gene on D15 may contribute to primary PH in the nitrofen CDH model by disrupting early lung morphogenesis. Upregulation of MK gene after RA treatment in the nitrofen-induced hypoplastic lung suggests that RA may have a therapeutic potential to rescue PH in CDH through RA-responsive growth factor signaling.
硝基芬诱导的先天性膈疝(CDH)模型已被广泛用于研究CDH中肺发育不全(PH)的发病机制。最近的研究表明,视黄酸可能参与CDH中PH的分子机制。据报道,在硝基芬CDH模型中,产前用视黄酸(RA)治疗可促进发育不全肺的生长。中期因子(MK)是一种RA反应性生长因子,在包括肺发育在内的各种器官发生过程中起关键作用。在胎儿肺中,MK mRNA表达在E13.5 - E16.5达到峰值,并在妊娠中后期显著下降,表明其在早期肺形态发生中起重要作用。我们设计本研究以探讨在硝基芬诱导的PH早期肺形态发生过程中肺MK基因表达下调的假说,并评估产前RA治疗对硝基芬诱导的CDH模型中肺MK基因表达的影响。
妊娠第9天(D9),将孕鼠暴露于橄榄油或硝基芬。在D15、D18和D21收集胎儿肺,并分为对照组、有或无CDH的硝基芬组[CDH(+)或CDH(-)]。此外,在D18、D19和D20给予RA,并在D21收集胎儿肺,然后分为对照组 + RA和硝基芬 + RA组。通过实时RT-PCR评估MK的肺基因表达水平并进行统计学分析。还进行免疫组织化学检查MK在胎儿肺中的蛋白表达/分布。
与对照组相比,硝基芬组在D15时MK的相对mRNA表达水平显著下调((§)p < 0.01),而在D18和D21时无显著差异。与对照组(0.35 ± 0.16)、CDH(-)组(0.24 ± 0.15)、CDH(+)组(0.39 ± 0.19)和对照组 + RA组(0.47 ± 0.13)相比,硝基芬 + RA组(0.71 ± 0.17)的MK基因表达水平显著上调(*p < 0.05)。与对照组相比,硝基芬肺中MK的免疫反应性在D15时也显著降低,与其他肺相比,硝基芬 + RA肺中MK的免疫反应性在D21时增加。
D15时MK基因的下调可能通过破坏早期肺形态发生而导致硝基芬CDH模型中的原发性PH。在硝基芬诱导的发育不全肺中,RA治疗后MK基因上调表明RA可能具有通过RA反应性生长因子信号传导挽救CDH中PH的治疗潜力。